BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18793708)

  • 1. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer.
    Onyüksel H; Mohanty PS; Rubinstein I
    Int J Pharm; 2009 Jan; 365(1-2):157-61. PubMed ID: 18793708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer.
    Saxena V; Naguib Y; Hussain MD
    Colloids Surf B Biointerfaces; 2012 Jun; 94():274-80. PubMed ID: 22377218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme.
    Saxena V; Hussain MD
    Colloids Surf B Biointerfaces; 2013 Dec; 112():350-5. PubMed ID: 24012704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting breast cancer using pirarubicin-loaded vasoactive intestinal peptide grafted sterically stabilized micelles.
    Eskandari Z; Bahadori F; Yapaoz MA; Yenigun VB; Celikten M; Kocyigit A; Onyuksel H
    Eur J Pharm Sci; 2021 Jul; 162():105830. PubMed ID: 33819623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular delivery of VIP-grafted sterically stabilized phospholipid mixed nanomicelles in human breast cancer cells.
    Rubinstein I; Soos I; Onyuksel H
    Chem Biol Interact; 2008 Jan; 171(2):190-4. PubMed ID: 17499651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG.
    Wang S; Wang X; Du Z; Liu Y; Huang D; Zheng K; Liu K; Zhang Y; Zhong X; Wang Y
    Biochem Biophys Res Commun; 2014 Jul; 450(1):73-80. PubMed ID: 24879994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
    Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
    Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer.
    Ghalhar MG; Akbarzadeh A; Rahmati M; Mellatyar H; Dariushnejad H; Zarghami N; Barkhordari A
    Asian Pac J Cancer Prev; 2014; 15(17):7113-8. PubMed ID: 25227799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
    J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
    Roforth MM; Tan C
    Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells.
    Onyüksel H; Jeon E; Rubinstein I
    Cancer Lett; 2009 Feb; 274(2):327-30. PubMed ID: 19022562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
    Koo OM; Rubinstein I; Onyuksel H
    Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.
    Xu Y; Zhu Q; Chen D; Shen Z; Wang W; Ning G; Zhu Y
    Tumour Biol; 2015 Jul; 36(7):5103-8. PubMed ID: 25682284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
    Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
    J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epothilone B-based 3-in-1 polymeric micelle for anticancer drug therapy.
    Shin DH; Kwon GS
    Int J Pharm; 2017 Feb; 518(1-2):307-311. PubMed ID: 28062368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells.
    Gülçür E; Thaqi M; Khaja F; Kuzmis A; Önyüksel H
    Drug Deliv Transl Res; 2013 Dec; 3(6):. PubMed ID: 24363979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent cytotoxic C-11 modified geldanamycin analogues.
    Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
    J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxygeldanamycin (17-AAG).
    Chandran T; Katragadda U; Teng Q; Tan C
    Int J Pharm; 2010 Jun; 392(1-2):170-7. PubMed ID: 20363305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.
    Zhang T; Li Y; Zhu Z; Gu M; Newman B; Sun D
    Mol Pharm; 2010 Oct; 7(5):1576-84. PubMed ID: 20669973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of Folic Acid-Targeted Temperature-Sensitive Magnetoliposomes and their Antitumor Effects In Vitro and In Vivo.
    Wang X; Yang R; Yuan C; An Y; Tang Q; Chen D
    Target Oncol; 2018 Aug; 13(4):481-494. PubMed ID: 29992403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.